[1] |
Gao XM, Li J, Cao XX. Signaling pathways, microe-nvironment, and targeted treatments in Langerhans cell histiocytosis[J]. Cell Commun Signal, 2022, 20(1): 195.
|
[2] |
Bielamowicz K, Dimitrion P, Abla O, et al. Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures[J]. Cancer, 2024, 130(14): 2416-2439.
|
[3] |
Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis[J]. Blood, 2013, 121(25): 5006-5014.
doi: 10.1182/blood-2012-09-455774
pmid: 23589673
|
[4] |
Tantawy AAG, Ragab IA, Elsherif NHK, et al. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates[J]. Pediatr Hematol Oncol, 2020, 37(8): 696-706.
|
[5] |
Tang JJ, Xu XJ, Wang YC, et al. Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children[J]. Zhonghua Erke Zazhi, 2021, 59(1): 37-41.
|
[6] |
Cui L, Wang CJ, Lian HY, et al. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: results from the BCH-LCH 2014 protocol study[J]. Am J Hematol, 2023, 98(4): 598-607.
doi: 10.1002/ajh.26829
pmid: 36594188
|
[7] |
Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study[J]. Blood, 2015, 126(12): 1415-1423.
doi: 10.1182/blood-2015-03-635151
pmid: 26194764
|
[8] |
Irie M, Nakano T, Katayama S, et al. Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis[J]. Cancer Rep (Hoboken), 2022, 5(8): e1579.
|
[9] |
Cournoyer E, Ferrell J, Sharp S, et al. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders[J]. Haematologica, 2024, 109(4): 1137-1148.
|
[10] |
Eder SK, Schwentner R, Ben Soussia P, et al. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis[J]. Blood Adv, 2022, 6(3): 970-975.
|
[11] |
Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study[J]. J Clin Oncol, 2019, 37(31): 2857-2865.
doi: 10.1200/JCO.19.00456
pmid: 31513482
|
[12] |
Evseev D, Kalinina I, Raykina E, et al. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA[J]. Int J Hematol, 2021, 114(6): 725-734.
|
[13] |
Mohapatra D, Gupta AK, Haldar P, et al. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): a systematic review and meta-analysis[J]. Pediatr Hematol Oncol, 2023, 40(1): 86-97.
|
[14] |
Yang Y, Wang D, Cui L, et al. Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAFV600E-Mutated Langerhans cell histiocytosis[J]. Cancer Res Treat, 2021, 53(1): 261-269.
|
[15] |
Wahba A, Cuglievan B. Central nervous system Langerhans cell histiocytosis and neurodegenerative syndrome responding to MEK inhibition[J]. EJHaem, 2021, 2(4): 881-882.
doi: 10.1002/jha2.294
pmid: 35845219
|
[16] |
Roeser A, Jouenne F, Vercellino L, et al. Dramatic response after switching MEK inhibitors in a patient with refractory mixed histiocytosis[J]. J Hematol, 2022, 11(5): 185-189.
|
[17] |
Du Y, Hu YT. Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis[J]. Am J Transl Res, 2022, 14(12): 8768-8772.
pmid: 36628254
|
[18] |
van Landingham SW, Puccetti D, Potter H, et al. Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment[J]. Am J Ophthalmol Case Rep, 2020, 20: 100868.
|
[19] |
Wajda N, Zhu Z, Jandarov R, et al. Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis[J]. Respirology, 2020, 25(6): 644-650.
doi: 10.1111/resp.13671
pmid: 31407478
|
[20] |
Ziogas IA, Kakos CD, Wu WK, et al. Liver transplantation for Langerhans cell histiocytosis: a US population-based analysis and systematic review of the literature[J]. Liver Transpl, 2021, 27(8): 1181-1190.
|
[21] |
Pan Y, Xi R, Wang C, et al. Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk, BRAF V600E-negative Langerhans cell histiocytosis[J]. J Int Med Res, 2019, 47(9): 4522-4529.
|
[22] |
Kudo K, Maeda M, Suzuki N, et al. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis[J]. Int J Hematol, 2020, 111(1): 137-148.
doi: 10.1007/s12185-019-02760-5
pmid: 31758416
|
[23] |
Khandelwal V, Choudhary D, Kumar Sharma S, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide in pediatric refractory Langerhans cell histiocytosis: a case report[J]. Pediatr Blood Cancer, 2021, 68(3): e28746.
|
[24] |
Tang X, Gao J, Ma ZG, et al. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020[J]. Ann Med, 2021, 53(1): 1537-1546.
doi: 10.1080/07853890.2021.1966085
pmid: 34459688
|
[25] |
Uppuluri R, Ramachandrakurup S, Subburaj D, et al. Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children[J]. Pediatr Blood Cancer, 2017, 64(1): 110-112.
doi: 10.1002/pbc.26199
pmid: 27555565
|
[26] |
Kudo K, Tanaka T, Kobayashi A, et al. Zoledronic acid for relapsed Langerhans cell histiocytosis with isolated skull bone lesion[J]. Pediatr Int, 2019, 61(3): 315-317.
doi: 10.1111/ped.13774
pmid: 30793439
|
[27] |
Montella L, Ottaviano M, Riccio V, et al. Results of TETimaX trial of Langerhans cell histiocytosis treatment and perspectives on the role of imatinib mesylate in the era of MAPK signaling[J]. Biomedicines, 2021, 9(12): 1759.
|
[28] |
Dhir A, Kelly DR, Watts RG, et al. Recurrent skin Langerhan cell histiocytosis successfully treated with indomethacin monotherapy[J]. J Pediatr Hematol Oncol, 2020, 42(8): e795-e797.
|
[29] |
Åkefeldt SO, Ismail MB, Belot A, et al. Neutralizing anti-IL-17A antibody demonstrates preclinical activity enhanced by vinblastine in Langerhans cell histiocytosis[J]. Front Oncol, 2021, 11: 780191.
|
[30] |
Tomasian A, Hillen TJ, Jennings JW. Unifocal Langerhans cell histiocytosis of bone: percutaneous navigational bipolar radiofrequency ablation for curative treatment[J]. Clin Imaging, 2021, 72: 55-57.
|
[31] |
Papavasiliou K, Bintoudi A, Vlahodimos A, et al. Localized chronic form of Langerhans cell histiocytosis in the femur of a 16-year-old male successfully treated with radiofrequency ablation[J]. Case Rep Oncol Med, 2020, 2020: 4052034.
|
[32] |
Abeykoon JP, Lasho TL, Dasari S, et al. Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease[J]. Am J Hematol, 2022, 97(3): 293-302.
doi: 10.1002/ajh.26441
pmid: 34978715
|